It has been reported that an activity change in the IL6/JAK/STAT3 signaling pathway can regulate liver hepatocellular carcinoma, chronic myeloid leukemia, and glioma (Yao et al., 2016; Yang et al., 2018; Ni et al., 2020). This evidence concerns the gene IL6 and central nervous system cancer.